-
公开(公告)号:US10894851B2
公开(公告)日:2021-01-19
申请号:US16085809
申请日:2017-03-16
IPC分类号: C08F212/00 , C08F212/14 , C13K1/02 , C08F12/26 , C08F212/34 , D21C5/00 , C08F12/30 , D21C3/22 , D21C3/20 , C13K13/00 , D21C11/00 , B01J31/06 , B01J35/06 , C07C51/487 , C07D307/44 , C07D307/50 , C08F236/20
摘要: Ionic polymers (IP) are made of anions and a polymeric backbone containing cations. The ionic polymers are incorporated in membranes or attached to solid supports and use of the ionic polymers in processing of biomass.
-
公开(公告)号:US20170014372A1
公开(公告)日:2017-01-19
申请号:US15124039
申请日:2015-03-12
发明人: Patrycja Nowak-Sliwinska , Paul Dyson , Arjan Griffioen , Andrea Weiss , Hubert Van den Bergh , Xianting Ding
IPC分类号: A61K31/28 , A61K31/4745 , A61K31/517
CPC分类号: A61K31/28 , A61K31/00 , A61K31/4745 , A61K31/517 , A61K45/06 , A61K2300/00
摘要: Angiogenesis inhibitory drug combination obtained according to a specific algorithm, preferably a FSC, in which an initial combination of drugs is iteratively adjusted. The drug combination according to the invention may advantageously comprise a RAPTA-C compound. In a more specific case the combination comprises RAPTA-C and eriotinib.
摘要翻译: 根据特定算法(优选FSC)获得的血管发生抑制药物组合,其中药物的初始组合被迭代地调整。 根据本发明的药物组合可以有利地包含RAPTA-C化合物。 在更具体的情况下,组合包含RAPTA-C和埃替奥替尼。
-